ARRDC1 Knockout HCT 116 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HCT 116 human colorectal carcinoma line, in which the ARRDC1 gene has been disrupted to create a heterogeneous loss-of-function model. This polyclonal format preserves allelic diversity and is ideal for studying the collective impact of ARRDC1 deficiency on signal transduction and tumor cell behavior without clonal selection biases.
HCT 116 is an epithelial colorectal carcinoma cell line exhibiting microsatellite instability (MSI) due to MLH1 mutation and an oncogenic CTNNB1 (??-catenin) mutation driving constitutive Wnt pathway activation. These features make it a widely used model for colorectal cancer research, particularly for investigating Wnt-dependent proliferation and apoptosis. The adherent morphology and stable growth characteristics support reproducible mechanistic and pharmacological studies.
ARRDC1 encodes an arrestin-domain-containing adaptor that links activated plasma membrane receptors to NEDD4 family ubiquitin ligases (NEDD4, NEDD4L, ITCH), promoting ubiquitination and lysosomal degradation of targets such as Notch, GPCRs, Dishevelled, and Smoothened (SMO). Through interactions with ALIX and TSG101, ARRDC1 directs receptors into multivesicular bodies, thus attenuating downstream signaling including NICD-mediated transcription, ??-catenin stabilization, and GLI transcriptional responses. This positions ARRDC1 as a key negative regulator of multiple morphogenic pathways.
In the HCT 116 background, where mutant ??-catenin sustains Wnt target gene expression, ARRDC1 disruption is expected to perturb Notch and Hedgehog pathway degradation and alter GPCR trafficking. The resultant polyclonal knockout population enables examination of how loss of this regulatory node reshapes signaling crosstalk and affects colorectal cancer phenotypes such as proliferation, apoptosis, and migration. The MSI status further allows exploration of DNA repair defect interactions with altered signal transduction.
Applications include monitoring ??-catenin and NICD abundance by western blotting, measuring target gene induction (MYC, CCND1, HES1) by RT-qPCR, and assessing TCF/LEF transcriptional activity via luciferase reporter assays. Co-immunoprecipitation can detect residual NEDD4 complexes, while flow cytometry quantifies cell cycle and apoptosis changes. Functional assays??wound healing, transwell migration??and drug sensitivity screens (5-FU, oxaliplatin) characterize chemoresistance. This polyclonal knockout model also suits genetic modifier screens targeting the ARRDC1?CNEDD4 axis. For more information, contact Ascent Research.
